Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Guardian Pharmacy Services (GRDN) Other Accumulated Expenses (2023 - 2025)

Guardian Pharmacy Services (GRDN) has disclosed Other Accumulated Expenses for 3 consecutive years, with $22.3 million as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses rose 9.12% to $22.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $22.3 million through Dec 2025, up 9.12% year-over-year, with the annual reading at $22.3 million for FY2025, 9.12% up from the prior year.
  • Other Accumulated Expenses hit $22.3 million in Q4 2025 for Guardian Pharmacy Services, up from $17.6 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $26.5 million in Q1 2025 to a low of $14.5 million in Q2 2025.
  • Historically, Other Accumulated Expenses has averaged $19.0 million across 3 years, with a median of $17.6 million in 2025.
  • Biggest five-year swings in Other Accumulated Expenses: rose 25.79% in 2024 and later grew 9.12% in 2025.
  • Year by year, Other Accumulated Expenses stood at $16.2 million in 2023, then grew by 25.79% to $20.4 million in 2024, then grew by 9.12% to $22.3 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for GRDN at $22.3 million in Q4 2025, $17.6 million in Q3 2025, and $14.5 million in Q2 2025.